| アブストラクト | OBJECTIVE: Diabetes has emerged as an important risk factor for mortality from COVID-19. Metformin, the most commonly prescribed glucose-lowering agent, has been proposed to influence susceptibility to and outcomes of COVID-19 via multiple mechanisms. We investigated whether, in patients with diabetes, metformin is associated with susceptibility to COVID-19 and its outcomes. RESEARCH DESIGN AND METHODS: We performed a propensity score-matched cohort study with active comparators using a large UK primary care dataset. Adults with type 2 diabetes patients and a current prescription for metformin and other glucose-lowering agents (MF+) were compared to those with a current prescription for glucose-lowering agents that did not include metformin (MF-). Outcomes were confirmed COVID-19, suspected/confirmed COVID-19, and associated mortality. A negative control outcome analysis (back pain) was also performed. RESULTS: There were 29 558 and 10 271 patients in the MF+ and MF- groups, respectively, who met the inclusion criteria. In the propensity score-matched analysis, the adjusted hazard ratios for suspected/confirmed COVID-19, confirmed COVID-19, and COVID-19-related mortality were 0.85 (95% CI 0.67, 1.08), 0.80 (95% CI 0.49, 1.30), and 0.87 (95% CI 0.34, 2.20) respectively. The negative outcome control analysis did not suggest unobserved confounding. CONCLUSION: Current prescription of metformin was not associated with the risk of COVID-19 or COVID-19-related mortality. It is safe to continue prescribing metformin to improve glycemic control in patients with. |
|---|
| ジャーナル名 | The Journal of clinical endocrinology and metabolism |
|---|
| Pubmed追加日 | 2021/2/10 |
|---|
| 投稿者 | Wang, Jingya; Cooper, Jennifer M; Gokhale, Krishna; Acosta-Mena, Dionisio; Dhalla, Samir; Byne, Nathan; Chandan, Joht Singh; Anand, Astha; Okoth, Kelvin; Subramanian, Anuradhaa; Bangash, Mansoor N; Jackson, Thomas; Zemedikun, Dawit; Taverner, Tom; Hanif, Wasim; Ghosh, Sandip; Narendran, Parth; Toulis, Konstantinos A; Tahrani, Abd A; Surenthirakumaran, Rajendra; Adderley, Nicola J; Haroon, Shamil; Khunti, Kamlesh; Sainsbury, Christopher; Thomas, G Neil; Nirantharakumar, Krishnarajah |
|---|
| 組織名 | Institute of Applied Health Research, University of Birmingham, Birmingham, UK.;Cegedim Health Data, Cegedim Rx, London, UK.;The Health Improvement Network (THIN), London, UK.;Institute of Clinical Sciences, University of Birmingham, Birmingham, UK.;Department of Critical Care, University Hospitals Birmingham NHS Foundation;Trust, Birmingham, UK.;Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.;Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS;Foundation Trust, Birmingham, UK.;Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham,;UK.;Institute of Metabolism and Systems Research, University of Birmingham,;Birmingham, UK.;Centre for Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham Health;Partners, Birmingham, UK.;Department of Community and Family Medicine, Faculty of Medicine, University of;Jaffna, Jaffna, Sri Lanka.;Diabetes Research Centre, University of Leicester, Leicester.;Department of Diabetes, Gartnavel General Hospital, NHS Greater Glasgow and;Clyde, Glasgow, UK.;Midlands Health Data Research UK, Birmingham, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/33560344/ |
|---|
